AU2013349804A1 - Saquinavir-no for immunomodulation - Google Patents

Saquinavir-no for immunomodulation Download PDF

Info

Publication number
AU2013349804A1
AU2013349804A1 AU2013349804A AU2013349804A AU2013349804A1 AU 2013349804 A1 AU2013349804 A1 AU 2013349804A1 AU 2013349804 A AU2013349804 A AU 2013349804A AU 2013349804 A AU2013349804 A AU 2013349804A AU 2013349804 A1 AU2013349804 A1 AU 2013349804A1
Authority
AU
Australia
Prior art keywords
saq
saquinavir
disease
cells
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013349804A
Other languages
English (en)
Inventor
Ferdinando Nicoletti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onconox APS
Original Assignee
Onconox APS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconox APS filed Critical Onconox APS
Publication of AU2013349804A1 publication Critical patent/AU2013349804A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2013349804A 2012-11-20 2013-11-20 Saquinavir-no for immunomodulation Abandoned AU2013349804A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728330P 2012-11-20 2012-11-20
US61/728,330 2012-11-20
PCT/EP2013/074264 WO2014079868A1 (en) 2012-11-20 2013-11-20 Saquinavir-no for immunomodulation

Publications (1)

Publication Number Publication Date
AU2013349804A1 true AU2013349804A1 (en) 2015-06-04

Family

ID=49759262

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013349804A Abandoned AU2013349804A1 (en) 2012-11-20 2013-11-20 Saquinavir-no for immunomodulation

Country Status (11)

Country Link
US (1) US20150283127A1 (enExample)
EP (1) EP2922545B1 (enExample)
JP (1) JP6283680B2 (enExample)
KR (1) KR20150084862A (enExample)
CN (1) CN104822379B (enExample)
AU (1) AU2013349804A1 (enExample)
BR (1) BR112015011299A2 (enExample)
CA (1) CA2891771A1 (enExample)
IL (1) IL238866A0 (enExample)
MX (1) MX2015006249A (enExample)
WO (1) WO2014079868A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104127858A (zh) * 2014-07-26 2014-11-05 滨州医学院 甲磺酸沙奎拉韦在制备预防或治疗内毒素血症和脓毒症的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003674T2 (tr) * 1998-06-09 2001-07-23 J. Embro William Epidermal iltihapların ve enfeksiyonların tedavisine yönelik metot.
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
US20030138423A1 (en) * 2001-12-14 2003-07-24 Cedars-Sinai Medical Center Method of treating inflammation with HIV-1 protease inhibitors and their derivatives
HRP20140929T1 (hr) * 2008-08-01 2014-12-05 Onconox Aps Antitumorska svojstva no-modificiranih inhibitora proteaze
WO2012088305A1 (en) * 2010-12-22 2012-06-28 The Feinstein Institute For Medical Research Methods for treating systemic lupus erythematosus using hiv protease inhibitors

Also Published As

Publication number Publication date
JP2015537023A (ja) 2015-12-24
WO2014079868A1 (en) 2014-05-30
IL238866A0 (en) 2015-06-30
CN104822379A (zh) 2015-08-05
JP6283680B2 (ja) 2018-02-21
US20150283127A1 (en) 2015-10-08
MX2015006249A (es) 2015-12-03
EP2922545B1 (en) 2016-09-21
CN104822379B (zh) 2017-08-25
HK1212895A1 (zh) 2016-06-24
KR20150084862A (ko) 2015-07-22
EP2922545A1 (en) 2015-09-30
CA2891771A1 (en) 2014-05-30
BR112015011299A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
Basile et al. The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19
Jager et al. The kinase inhibitory region of SOCS-1 is sufficient to inhibit T-helper 17 and other immune functions in experimental allergic encephalomyelitis
Gao et al. Artemisinins: promising drug candidates for the treatment of autoimmune diseases
AU2014244744B2 (en) Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator T cells and promoting proliferation of regulator T cells
AU2019245521B2 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
CA2815542C (en) Use of a spironolactone-based composition that exhibits an inhibitory action on t-lymphocyte activation which is useful for preventing and/or treating multiple sclerosis
Bodar et al. Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra)
Shi et al. Compound Danshen Dripping Pill effectively alleviates cGAS-STING-triggered diseases by disrupting STING-TBK1 interaction
US5961977A (en) Method of treating or preventing autoimmune uveoretinitis in mammals
Petković et al. Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis
EP2922545B1 (en) Saquinavir-no for immunomodulation
JP2005511767A (ja) Ｈｉｖ−１プロテアーゼインヒビターおよびその誘導体の、炎症の処置における使用
Li et al. Curcumin improves experimentally induced colitis in mice by regulating follicular helper T cells and follicular regulatory T cells by inhibiting interleukin-21.
CN1146208A (zh) 用作自身免疫性疾病治疗剂的肽
CN109939119B (zh) 栀子苷在制备治疗多发性硬化症药物中的应用
Zimecki et al. Lactoferrin ameliorates symptoms of experimental encephalomyelitis in Lewis rats
EP0335726A2 (en) Use of thymopentin and derivatives in treatment of HIV viremic patients
Liang et al. T‐cell‐receptor dose and the time of treatment during murine retrovirus infection for maintenance of immune function
HK1212895B (en) Saquinavir-no for immunomodulation
EP3381934A1 (en) Protein for neutralizing programmed necrocytosis promotion antibody, and application of protein
Spadaro et al. Methotrexate effect on anti-cyclic citrullinated peptide antibody levels in rheumatoid arthritis
WO2015100150A1 (en) Oral administration of tocilizumab treatment of autoimmune disease
ES2257666T3 (es) Uso de (3-(2-etilfenil)-5-metoxifenil)-1h-(1,2,4)-triazol para el tratamiento de enfermedades autoinmunes.
Miescher et al. Autoimmune disorders: a concept of treatment based on mechanisms of disease
EP3621628A1 (en) Method for treating multiple sclerosis using arsenic trioxide

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period